Contribution. With Drew Weissman, she showed in 2005 what happens when some building blocks of synthetic mRNA (nucleosides) are replaced with modified versions found in nature, such as pseudouridine. The change greatly reduces the mRNA's activation of the innate immune system. That immune response had caused inflammation (Immunity, 2005). This made mRNA vaccines, including COVID-19 vaccines, possible. She shared the 2023 Nobel Prize in Physiology or Medicine with Weissman.
At a glance
Item
Detail
Dates
born 1955
Field
Medicine and public health
Case type
Pioneer
Discrimination or exclusion
Yes (suspected, not documented)
Factor coverage
Favorable entries (helped or barrier absent) and adverse entries (barrier or not overcome) by factor. Factor tags are this site's classification.
A modest start. She grew up in Kisújszállás, a town of about 10,000. She was the daughter of a butcher and a bookkeeper. Her home had no running water and no television. One of her teachers told her he would make sure she did not go to university (NobelPrize.org).
Funding loss and leaving Hungary. In 1985 her research group at the Biological Research Centre in Szeged ran out of funding. Her position was eliminated. In her own account, communist Hungary let emigrants take only $50 each, and the family had $100. They sold their car. They exchanged the money on the black market for about 800 British pounds (Nobel interview, 2023). They sewed it into their two-year-old daughter's teddy bear. NobelPrize.org's profile gives the sum as a little more than $1,000 (NobelPrize.org).
A hostile supervisor. According to her memoir, as summarized in a 2024 review in Emerging Infectious Diseases, her supervisor at Temple University screamed and threw objects at her. The same account says that when she tried to leave, the supervisor threatened to have her deported.
Rejection and demotion at Penn. She worked at the University of Pennsylvania from 1989. There her grant applications were rejected one after another. This was because few scientists thought unstable mRNA could become a medicine (University of Szeged). In 1995 she was demoted off the path to a full professorship. That same year she had a cancer scare, and a visa problem held her husband in Hungary. She described being demoted four times.
Little interest in the 2005 finding. She and Weissman expected their 2005 finding to draw wide interest. But, in her words, "Nobody cared." A 2023 perspective in Frontiers in Immunology, citing the New York Times, reports that Nature and Science rejected the manuscript before Immunity published it.
A path for working-class students. From age 16 she spent two summers in university preparatory courses for children of working-class parents. In 1973 she ranked third of 15 students admitted to study biology at the University of Szeged. She earned a PhD in biochemistry there in 1982.
Early influences. Two things fed her interest in biology: a biology teacher, Albert Tóth, and her father's work as a butcher. At 16 she read a Hungarian translation of a book by the endocrinologist Hans Selye. He advised focusing on what one can change, and she later cited that advice.
Training in an RNA laboratory. Jenő Tomasz's group at the Biological Research Centre in Szeged worked on nucleotide chemistry. She first used a modified nucleoside there.
A chance meeting. In the late 1990s she met the immunologist Drew Weissman at a photocopier. On her advice, he switched his vaccine work from DNA to mRNA.
Persistence. After her demotion she kept "working like nothing happened." She and Weissman spent years finding the cause of the inflammation that synthetic mRNA caused in mice and in human immune cells.
A private-sector path. In 2013 she joined BioNTech in Mainz, Germany, as vice president. She became senior vice president in 2019. Her husband backed the move. She commuted between Philadelphia and Germany for about nine years.
She never held a tenured post. She stayed in non-tenured positions at Penn until 2013. That year the university declined to reinstate her former position and told her she was "not of faculty quality." She was forced to retire after 24 years. RNARx, the company she and Weissman founded, could not get the patent rights to their discovery. Penn owned those rights and licensed them.
Possible bias. Some commentators, including UC Berkeley biologist Michael Eisen, have suggested that she was penalized for being a woman and an immigrant from Eastern Europe (Times Higher Education). This is a suggestion, not a documented finding. Penn did not respond to questions. Penn says the Pfizer/BioNTech and Moderna vaccines use its licensed technology and that Penn, Karikó, and Weissman have received financial benefits from it. Her memoir, Breaking Through: My Life in Science, was published by Crown in 2023.
Discrimination and exclusion
Element
In this case
Form of exclusion
Repeated demotions. Bias against her as a female immigrant is suspected but not documented.
Modern evidence it parallels
Experimental evidence on gender bias in academic hiring is mixed (rated D and B). So the document does not treat bias as established in her case.
What got them past it
Her collaborator Drew Weissman and a private-sector path.
Also relevant: Bell, A., Chetty, R., Jaravel, X., Petkova, N., & Van Reenen, J. (2019). Who becomes an inventor in America? Quarterly Journal of Economics, 134(2), 647-713. All references